about
Phosphorylation of LRRK2 by casein kinase 1α regulates trans-Golgi clustering via differential interaction with ARHGEF7Cognitive profile of LRRK2-related Parkinson's diseaseLRRK2 at the interface of autophagosomes, endosomes and lysosomesAbnormal visual gain control in a Parkinson's disease model.Neuroimaging in pre-motor Parkinson's diseaseVPS35, the Retromer Complex and Parkinson's Disease.Activation of FADD-Dependent Neuronal Death Pathways as a Predictor of Pathogenicity for LRRK2 Mutations.Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S MutationCellular processes associated with LRRK2 function and dysfunctionMechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation.The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspotDopamine Induces Oscillatory Activities in Human Midbrain Neurons with Parkin Mutations.68 and FX2149 Attenuate Mutant LRRK2-R1441C-Induced Neural Transport Impairment.Whole-exome sequencing associates novel CSMD1 gene mutations with familial Parkinson diseaseComputational analysis of the LRRK2 interactome.LRRK2 Expression Is Deregulated in Fibroblasts and Neurons from Parkinson Patients with Mutations in PINK1.Mitochondria: A Common Target for Genetic Mutations and Environmental Toxicants in Parkinson's Disease.Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation.Parkinson's disease: From human genetics to clinical trials.The LRRK2 Variant E193K Prevents Mitochondrial Fission Upon MPP+ Treatment by Altering LRRK2 Binding to DRP1.Mutations in LRRK2 amplify cell-to-cell protein aggregate propagation: a hypothesis.Clinical Heterogeneity Among Variants in Parkinson's Disease: A Meta-AnalysisLeucine-rich repeat kinase 2 controls protein kinase A activation state through phosphodiesterase 4Isolated nigral degeneration without pathological protein aggregation in autopsied brains with LRRK2 p.R1441H homozygous and heterozygous mutationsA new hypothesis for Parkinson's disease pathogenesis: GTPase-p38 MAPK signaling and autophagy as convergence points of etiology and genomics
P2860
Q24309417-9304A81F-2BB3-4ACD-9F3A-D64107E4C2BAQ27333093-EDE84AB4-E13F-4E42-8804-AD857060BC41Q28078248-C758730F-AB83-46D1-9237-EC641FEC5309Q30585664-7E7FAB0F-FDB0-43AE-A88C-53EAE7B4A4FDQ33676222-2FDB4E8F-592A-44E6-AFF9-94CCBFA162E1Q33708940-52AE7120-708D-4EF2-82B8-8363926B2479Q36188579-8B027154-6812-4375-99D3-CE918DA9B3A1Q37080018-9A9936A1-0BD9-4BE0-8FAE-CE3308DD09C5Q38433725-303598E0-8B84-4D3D-8206-6F60599525CCQ39137358-C321B76E-403A-4811-B208-8FEAB4638D69Q40783163-9B00C306-CEB1-4EDF-9027-7E09A8ABEF70Q40989589-E32561E9-1F2A-4BFB-AE0A-9C26C4969E81Q41075418-7B342567-BFDA-4004-B5BB-CE2DD1853F2CQ41217598-916B19D6-C206-449C-9465-9F828EFCD82DQ41301744-9445956D-9D3D-41D9-AB5B-EBB86EC15B31Q42503075-990938B7-99FC-4425-9737-9EFAFBDCC57AQ47147993-63A5E06E-5F4B-425F-B0EC-00FD69670B2DQ48192270-AFEE1079-933E-49A0-931D-E4AF298AB5F5Q52149136-096A8E5B-B29A-4E15-90E7-C5CE5D1B3DE4Q52355227-8B81C571-0462-4702-B99E-98CD16855E61Q55122127-E2157283-B302-4797-9833-4871E41BD536Q57072461-77891438-DFEA-4443-ABA8-85D24996B854Q58111473-B7D52C36-B8D2-4AB1-A2CE-9D17FCE833BDQ58604362-C3F51E79-89CC-46AE-AA3E-4670A2BF6920Q58803163-B1601643-4462-4EC1-85D0-6B28A38664B6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
LRRK2: cause, risk, and mechanism.
@en
LRRK2: cause, risk, and mechanism.
@nl
type
label
LRRK2: cause, risk, and mechanism.
@en
LRRK2: cause, risk, and mechanism.
@nl
prefLabel
LRRK2: cause, risk, and mechanism.
@en
LRRK2: cause, risk, and mechanism.
@nl
P2860
P921
P356
P1476
LRRK2: cause, risk, and mechanism.
@en
P2093
Patrick A Lewis
P2860
P304
P356
10.3233/JPD-130192
P5008
P577
2013-01-01T00:00:00Z